A review of the long-term protection after hepatitis A and B vaccination

Travel Medicine and Infectious Disease

Volumn 5, Issue 2 SPEC. ISS., 2007, Pages 79-84

  Van Damme, Pierre ^a   Van Herck, Koen ^a  

^a WHO Collaborating Centre for Prevention and Control of Viral Hepatitis   (Belgium)

Author keywords

Duration; Hepatitis A vaccine; Hepatitis B vaccine; Protection

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC HEPATITIS; DISEASE CARRIER; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL STUDY; FOLLOW UP; HEPATITIS A; HEPATITIS A VIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOCOMPETENCE; INCIDENCE; LONG TERM CARE; MATHEMATICAL MODEL; MEMORY T LYMPHOCYTE; NONHUMAN; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; SINGLE DRUG DOSE; WORLD HEALTH ORGANIZATION;

EID: 33846826801     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2006.04.004     Document Type: Article

References (44)

1. Kao J.H., Hsu H.M., Shau W.Y., et al. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 139 (2001) 349-352
2. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000;355:561-5.
3. Jilg W., Schmidt M., and Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 6 (1988) 201-207
4. Banatvala J.E., and Van Damme P. Hepatitis B vaccine-do we need boosters?. J Viral Hepatitis 10 (2003) 1-6
5. Ayerbe M.C., Pérez-Rivilla A., and Icovahb Group. Assessment of long-term efficacy of hepatitis B vaccine. Eur J Epidemiol 17 (2001) 151-156
6. Chadha M.S., and Arankalle V.A. Ten-year serological follow-up of hepatitis B vaccine recipients. Indian J Gastroenterol 19 (2000) 168-171
7. West D.J., and Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14 (1996) 1019-1027
8. Banatvala J.E., Van Damme P., and Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 19 (2001) 877-885
9. Zanetti A., Mariano A., Romano L., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366 (2005) 1379-1384
10. Lin Y.C., Chang M.H., Ni Y.H., et al. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Inf Dis 187 (2003) 134-138
11. Yuen M.F., Lim W.L., Chan A.O., et al. 18 year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2 (2004) 941-945
12. McMahon B.J., Burden D.L., Petersen K.M., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15 year follow-up. Ann Intern Med 142 (2005) 333-341
13. Boland G.J., De Gast G.C., Italiander E., et al. Long-term immunity to hepatitis B infection after vaccination with recombinant hepatitis B vaccine. Hepatology 22 (1995) 325
14. Wismans P., van Hattum J., de Gast G.C., et al. A prospective study of in vitro anti-HBs producing B cells (Spot-ELISA) following primary and supplementary vaccination with recombinant hepatitis B vaccine in insulin-dependent diabetic patients and matched controls. J Med Virol 35 (1991) 216-222
15. Dentico P., Crovari P., Lai P.L., et al. Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres. Vaccine 20 (2002) 3725-3730
16. FitzSimons D., Francois G., Hall A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 23 (2005) 4158-4166
17. Chen D.S. Long-term protection of hepatitis B vaccine: lessons learnt from Alaskan experience after 15 years. Ann Intern Med 142 (2005) 384-385
18. Van Damme P., and Van Herck K. Effect of hepatitis A vaccination programs. JAMA 294 (2005) 246-248
19. Van Herck K., Van Damme P., Lievens M., and Stoffel M. Hepatitis A Vaccine: Indirect Evidence of Immune Memory 12 Years After the Primary Course. J Med Virol 72 (2004) 194-196
20. Van Herck K, Renard D, Molenberghs G, Van Damme P. Model-based estimates of long-term persistence of vaccine induced hepatitis A antibodies. In: Margolis H, Alter M, Liang T, Dienstag J, editors. Viral Hepatitis and Liver Diseases. Proceedings of the Tenth International Symposium on Viral Hepatitis and Liver Diseases, 9-13 April 2000, Atlanta, USA. International Medical Press, Atlanta, USA; 2002. p. 56-9.
21. Bovier P.A., Bock J., Loutan L., et al. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J Med Virol 68 (2002) 489-493
22. Vidor E., Dumas R., Porteret V., et al. Aventis Pasteur vaccines containing inactivated hepatitis A virus: a compilation of immunogenicity data. Eur J Clin Microbiol Infect Dis 23 (2004) 300-309
23. Van Herck K., Beutels P., Van Damme P., et al. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines. J Med Virol 60 (2002) 1-7
24. Landry P., Tremblay S., Darioli R., et al. Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose. Vaccine 19 (2001) 399-402
25. Iwarson S., Lindh M., and Widerstrom L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 11 (2004) 120-121
26. Williams J.L., Bruden D.A., Cagle H.H., et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 21 (2003) 3208-3211
27. Beck B.R., Hatz C., Brönnimann R., and Herzog C. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis a vaccine. CID 37 (2003) 126-128
28. Beck B.R., Hatz C.F., Loutan L., and Steffen R. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine. J Travel Med 11 (2004) 201-207
29. Purcell R.H., D'Hondt E., Bradbury R., et al. Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees. Vaccine 10 Suppl. 1 (1992) S148-S151
30. Chen X. The immune response to hepatitis A vaccination: studies in vivo and in vitro (1996), University Hospital, Utrecht
31. Lemon S.M. Immunologic approaches to assessing the response to inactivated hepatitis A vaccine. J Hepatol 18 Suppl. 2 (1993) S15-S19
32. Van Damme P., Banatvala J., Fay O., et al. Consensus Statement: hepatitis A booster vaccination: is there a need?. Lancet 362 (2003) 1065-1071
33. Thoelen S., Van Damme P., Leentvaar-Kuypers A., et al. The first combined vaccine against hepatitis A and B: an overview. Vaccine 17 (1999) 1657-1662
34. Van Damme P., Leroux-Roels G., Law B., et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 65 (2001) 6-13
35. Joines R.W., Blatter M., Abraham B., et al. A prospective, randomized, comparative US trial of a combined hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix) in adults. Vaccine 19 (2001) 4710-4719
36. Van Damme P., and Van Herck K. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines 3 (2004) 249-267
37. Zuckerman J., Connor B., and von Sonnenburg F. Hepatitis A and B booster recommendations: implications for travelers. CID 41 (2005) 1020-1026
38. Dagan R., Amir J., Mijalovsky A., et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 19 (2000) 1045-1052
39. Fiore A.E., Shapiro C., Sabin K.M., et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 22 (2003) 354-359
40. Chan C.Y., Lee S.D., Yu M.I., et al. Long-term follow-up of hepatitis A vaccination in children. Vaccine 17 (1999) 369-372
41. Fan P.C., Chang M.H., Lee P.I., et al. Follow-up immunogenicity of an inactivated hepatitis A virus vaccine in healthy children: results after 5 years. Vaccine 16 (1998) 232-235
42. Wiens B.L., Bohidar N.R., Pigeon J.G., et al. Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 49 (1996) 235-241
43. Van Herck K., and Van Damme P. Prevention of hepatitis A by Havrix: a review. Expert Rev Vaccines 4 (2005) 459-471
44. Rendi-Wagner P., Shouval D., Genton B., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24 (2006) 2781-2789